Treatment response in COPD: does FEV ₁ say it all? A post hoc analysis of the CRYSTAL study

Abstract

The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV ₁) in patients with chronic obstructive pulmonary disease (COPD) has rarely been investigated.

Using CRYSTAL, a 12-week open-label study in symptomatic, nonfrequently exacerbating patients with moderate COPD, we assessed at baseline the correlations between several PROs (Baseline Dyspnoea Index, modified Medical Research Council dyspnoea scale, COPD Assessment Test (CAT) and Clinical COPD Questionnaire (CCQ)), and between FEV ₁ and PROs. Associations between clinically relevant responses in FEV ₁, CAT, CCQ and Transition Dyspnoea Index (TDI) at week 12 were also assessed.

Using data from 4324 patients, a strong correlation was observed between CAT and CCQ (r _s=0.793) at baseline, with moderate or weak correlations between other PROs, and no correlation between FEV ₁ and any PRO. At week 12, 2774 (64.2%) patients were responders regarding TDI, CAT or CCQ, with 583 (13.5%) responding using all three measures. In comparison, 3235 (74.8%) were responders regarding FEV ₁, TDI, CAT or CCQ, with 307 (7.1%) responding concerning all four parameters.

Increases in lung function were accompanied by clinically relevant improvements of PROs in a minority of patients. Our results also suggest that PROs are not interchangeable. Thus, the observed treatment success in a clinical trial may depend on the selected parameters.

Abstract

Assessments of both lung function and various patient-reported outcomes in clinical trials may be necessary for a more complete picture of treatment response in patients with COPD and to guide treatment decisions http://ow.ly/msoz30nmupG